Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection

Transplantation

Volumn 96, Issue 4, 2013, Pages 413-420

  Banham, Gemma ^a   Prezzi, Davide ^a   Harford, Sarah ^a   Taylor, Craig J ^b   Hamer, Rizwan ^c   Higgins, Rob ^c   Bradley, J Andrew ^a   Clatworthy, Menna R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antibody incompatible transplantation; Antibody mediated rejection; B cells; BAFF

Indexed keywords

AZATHIOPRINE; B CELL ACTIVATING FACTOR; BASILIXIMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SOLUBLE B CELL ACTIVATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT REJECTION; ADULT; ANTIBODY COMPATIBLE RENAL TRANSPLANTATION; ANTIBODY INCOMPATIBLE RENAL TRANSPLANTATION; ANTIBODY ISOLATION; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DISEASE ASSOCIATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL GRAFT DYSFUNCTION; RISK ASSESSMENT; SINGLE DRUG DOSE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SOLUBILITY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84883449664     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318298dd65     Document Type: Article

References (30)

1. Stegall MD, Raghavaiah S, Gloor JM. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010.
2. Kirk AD, Turgeon NA, Iwakoshi NN. B cells and transplantation tolerance. Nat Rev Nephrol 2010; 6: 584.
3. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11: 1359.
4. Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231.
5. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198.
6. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006; 18: 284.
7. Ye Q,Wang L,Wells AD, et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004; 34: 2750.
8. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959.
9. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050: 34.
10. Gottenberg JE, Miceli-Richard C, Ducot B, et al. Markers of Blymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009; 11: R114.
11. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136: 309.
12. Parsons RF, Yu M, Vivek K, et al. Murine islet al.lograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation 2012; 93: 676.
13. Xu H, He X, Sun J, et al. The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 2009; 41: 112.
14. Xu H, He X, Liu Q, et al. Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with longterm outcome in kidney transplant recipients. Transplant Proc 2009; 41: 1552.
15. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85: 1648.
16. Thibault-Espitia A, Foucher Y, Danger R, et al. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant 2012; 12: 2754.
17. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721.
18. Zarkhin V, Li L, Sarwal MM. BAFF may modulate the rate of B-cell repopulation after rituximab therapy for acute renal transplant rejection. Transplantation 2009; 88: 1229.
19. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9: 1835.
20. Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30: 99.
21. Eilertsen GO, Van Ghelue M, Strand H, et al. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: A case-control study. Rheumatology (Oxford) 2011; 50: 2197.
22. Kawasaki A, Tsuchiya N, Fukazawa T, et al. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424.
23. Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006; 24: 983.
24. Gottenberg JE, Sellam J, Ittah M, et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cellactivating factor gene and primary Sjogren's syndrome. Arthritis Res Ther 2006; 8: R30.
25. Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC, et al. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000; 15: 502.
26. Pahl MV, Gollapudi S, Sepassi L, et al. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205.
27. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755.
28. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286.
29. Ginzler EM,Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res Ther 2012; 14: R33.
30. Higgins R, Lowe D, Hathaway M, et al. Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900.